TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04829162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother with obesity, daughter with obesity
Description: Participants in this group were shown an image of a mother with obesity and a daughter with obesity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother with obesity, daughter without obesity
Description: Participants in this group were shown an image of a mother with obesity and a daughter without obesity.
Study: NCT02551796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FS assisted laser in situ keratomileusis
Description: Track distance and spot distance will be 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter will be 8.0 mm, and flap thickness will be set to 105 μm. Side-cut angle and hinge angle will be 90°and 50° respectively. The flaps will be created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system will be used in the subsequent ablation of thstromal bed with a 6.0 mm optical zone. Once the excimer. ablation is completed, the flap will be repositioned in a similar fashion as in routine LASIK.
Study: NCT02901327

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Stabilisation Exercise
Description: McGill protocol starting with:~1. 'cat-camel' exercise exercise 10 repetitions with 7 seconds hold each~2. 'curl-up' exercise 10 repetitions with 7 seconds hold each~3. 'side-bridge' exercise 10 repetitions with 7 seconds hold each~4. 'cat-camel' exercise 10 repetitions with 7 seconds hold each progression was based on subjects' tolerance and endurance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: treadmill walk exercise
Description: Bruce protocol~This include:~1. '5 minutes warm up' at zero degree inclination.~2. '20 minutes active exercise with increasing speed and inclination'~3. '5 minutes cool down'
Study: NCT00984113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinogrel
Description: 100 mg elinogrel b.i.d. with aspirin q.d. for 7 days and aspirin alone for 4 days (Dose of aspirin is 81 mg in the US and 100 mg in Germany)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinogrel
Description: 100 mg elinogrel b.i.d. with aspirin q.d. for 7 days and aspirin alone for 4 days (Dose of aspirin is 81 mg in the US and 100 mg in Germany)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinogrel
Description: 100 mg elinogrel b.i.d. with aspirin q.d. for 7 days and aspirin alone for 4 days (Dose of aspirin is 81 mg in the US and 100 mg in Germany)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinogrel
Description: 100 mg elinogrel b.i.d. with aspirin q.d. for 7 days and aspirin alone for 4 days (Dose of aspirin is 81 mg in the US and 100 mg in Germany)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinogrel
Description: 100 mg elinogrel b.i.d. with aspirin q.d. for 7 days and aspirin alone for 4 days (Dose of aspirin is 81 mg in the US and 100 mg in Germany)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinogrel
Description: 100 mg elinogrel b.i.d. with aspirin q.d. for 7 days and aspirin alone for 4 days (Dose of aspirin is 81 mg in the US and 100 mg in Germany)
Study: NCT04193462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-partum depression- Dyadic psychotherapy-
Description: Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity. Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant. During the whole therapy-trial, the therapist will also use cognitive-behavioral approach to address the mother's perception of her infant and of herself as a mother.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-partum depression- Psycho-educational therapy
Description: Mothers will receive a therapy in their homes for 8 weeks, 1.5 hours for each session by a therapist arriving at their home. Each session will address a different developmental aspects of the baby (feeding, movement, social-emotional development etc.). Therapist will ask the mother about her baby, will give information about developmental needs and expectations and will help mother to enrich child's development and deal will potential problems
Study: NCT02208687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energetic
Description: Physiotherapy and occupational therapy aimed at reconditioning and social participation.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Usual care
Study: NCT03905044

Intervention type: OTHER
Intervention: eyes with congenital cataracts
Description: observation
Study: NCT00213993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiperspirant
Description: antiperspirant topically once daily to one foot
Study: NCT03927560

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Assisted Percutaneous Coronary Intervention
Description: Robotic Assisted Percutaneous Coronary Intervention
Study: NCT04935645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: PMR is a technique that provides relaxation in the whole body by voluntary and regular relaxation of large muscle groups in the human body, which is included in mind-body applications.
Study: NCT03686267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: opaqued titanium abutments
Description: masking metallic color of titanium abutments by opaque porcelain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lithium disilicate coping (high opacity)
Description: masking metallic color of titanium abutments using lithium disilicate copings

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: titanium abutment with no color masking
Description: color masking methods are avoided in this arm
Study: NCT01813994

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Arm2: Placebo
Description: Study1 (only H. pylori infected patients) Arm2: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take placebos for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm2: In this arm2, all patients start taking placebos after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection.
Study: NCT04653467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG4399 oral suspension
Description: GLPG4399 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG4399 oral suspension
Description: GLPG4399 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG4399 oral suspension
Description: GLPG4399 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG4399 oral suspension
Description: GLPG4399 for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG4399 capsules
Description: GLPG4399 for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral suspension
Study: NCT01117909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization therapy in addition to standard therapy
Description: Subject will receive three 60-second bouts of posterior joint mobilizations applied to the ankle joint during each treatment session. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham intervention
Description: Physical therapist will lay hands as if to perform the joint mobilization but no movement will occur.
Study: NCT00220922

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alcohol Wipes vs. No Alcohol Wipes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alcohol Wipes vs. No Alcohol Wipes
Study: NCT01426542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate 5 mg/kg by mouth (or by feeding tube) once a day for one week before and one week after heart surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No medication, but routine heart surgery
Description: No medication, but routine heart surgery
Study: NCT05185206

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Class 1 cavity preparation using conventional steel bur and restoration with Cention-n(commercially available restorative material).
Description: Patients aged between 18 and 55 years having class 1 occlusal caries(1.2 according to G. J. Mount classification) on both sides of arch. In order to standardise the cavity preparation depth(approximately 1.5 to 2mm from the roof of the pulp chamber), the distance from occlusal surface to roof of pulp chamber will be used for measuring with the radiograph. This will be followed by caries removal with convention steel bur followed by restoration with Cention-n and checking of postoperative sensitivity using Visual Analog Scale.The Visual Analog Scale consists of a 100-mm line divided into equal intervals of 10 mm, where 0 represents absence of pain and 100 severe pain. The results of Visual Analog Scale will be classified as mild (0-30 mm), moderate (40-70 mm), or severe pain (\> 70 mm).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Class 1 cavity preparation using polymer bur and restoration with Cention-n(commercially available restorative material).
Description: Patients aged between 18 and 55 years having class 1 occlusal caries(1.2 according to G. J. Mount classification) on both sides of arch. In order to standardise the cavity preparation depth(approximately 1.5 to 2mm from the roof of the pulp chamber), the distance from occlusal surface to roof of pulp chamber will be used for measuring with the radiograph. This will be followed by caries removal with polymer bur followed by restoration with Cention-n and checking of postoperative sensitivity using Visual Analog scale.The Visual Analog Scale consists of a 100-mm line divided into equal intervals of 10 mm, where 0 represents absence of pain and 100 severe pain. The results of Visual Analog Scale will be classified as mild (0-30 mm), moderate (40-70 mm), or severe pain (\> 70 mm).
Study: NCT02586506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ELLIPTA inhaler
Description: The ELLIPTA Dry Powder Inhaler (DPI) is a molded plastic two-sided inhaler that can hold two individual blister strips. Each strip will contain either lactose or a blend of lactose and magnesium stearate. Subjects will receive 1 inhalation once-daily until visit 2.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
Study: NCT01566214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: For those subjects randomly assigned to the treatment group, information from their MIHART assessment interview and medical record review will be used to select intervention scripts optimally tailored to each subjects' unique configuration of beliefs and risk factors and they will be re-contacted by telephone at 2-weeks post-hospital discharge to deliver the Vet-HART intervention. The intervention will be administered by a trained research assistant via telephone, working from a semi-structured script tailored to each subject's representations and risk factors, the call will last about 15-30 minutes.
Study: NCT03540251

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Auricular Points Sticking
Description: Auricular Points Sticking is a kind of acupunture based on Meridians Theory of traditional Chinese Medicine.Sticking and pressing predefined therapeutic auricular points can relieve the frequency and severity of hot flashes and other climacteric symptoms.~Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets.In addition, both group received 8 treatment sessions of sticking and pressing predefined auricular points or placebo auricular points treatments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auricular Points Sticking
Description: Auricular Points Sticking is a kind of acupunture based on Meridians Theory of traditional Chinese Medicine.Sticking and pressing predefined therapeutic auricular points can relieve the frequency and severity of hot flashes and other climacteric symptoms.~Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets.In addition, both group received 8 treatment sessions of sticking and pressing predefined auricular points or placebo auricular points treatments.
Study: NCT00316108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WALLSTENT® Endoprosthesis™
Description: Carotid Artery Stent
Study: NCT04734678

Intervention type: DRUG
Intervention: Tocilizumab
Description: 400 mg IV only once

Intervention type: DRUG
Intervention: Tocilizumab
Description: 400 mg IV only once

Intervention type: DRUG
Intervention: Infliximab
Description: 5 mg/kg/day IV for 2 doses 12-24 hours
Study: NCT00393510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCM
Description: The Decoction is taken orally, twice a day, treatment period is 24 weeks The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.~The formula consisted of 12 herbs, viz:~Radix astragali, Rhizoma atractylodis marcocephalae, Radix stephaniae tetrandrae, Radix polygoni multiflori, Radix rehmanniae, Radix smilax china, Fructus corni, Rhizoma dioscoreae, Cortex moutan, Rhizoma alismatis, Rhizoma smilacis glabrae, and Fructus schisandrae

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taking orally, twice a day, 24 week treatment period The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.~The placebo was made with starch and colouring materials.
Study: NCT01297777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: * In patients without B or C findings and without biological progression: 300 mg/24 h p.o during one year or until progression/unacceptable toxicity.~* In patients with B or C findings or biological progression: 300 mg/24 h p.o for two weeks and then 400 mg/24 h p.o for a total of one year of therapy, or until progression/unacceptable toxicity.
Study: NCT01073046

Intervention type: DEVICE
Intervention: Naso-Gastric/Jejunal Tube
Description: Silastic Naso-Gastric/Jejunal Tube (Rusch® distributed by Teleflex Medical Srl)
Study: NCT04335214

Intervention type: OTHER
Group type: OTHER
Intervention: one to one interview
Description: one to one interviews with older people from moroccon origin in Belgium
Study: NCT01402856

Intervention type: OTHER
Intervention: Education
Description: An educational program targeting HS students on the risks of distracted driving that was 60-min long \& utilized: a 5-10 min DVD on a teenager's real-life experience of the devastating effects of distracted driving, other videos placing the viewer in the driver's seat, power point presentations of state and national statistics related to seat belt usage, mortality, and substance use, overview of state laws, demonstrations of the physics of an accident, \& interactive games simulating distracted driving.
Study: NCT01402336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (Cetrorelix)
Description: In the first arm, cetrotide will be administrated from the first day during stimulation. In the second arm, cetrotide will be administrated from the sixth day during stimulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (Cetrorelix)
Description: In the first arm, cetrotide will be administrated from the first day during stimulation. In the second arm, cetrotide will be administrated from the sixth day during stimulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional GnRH agonist (Triptorelin)
Description: Patients in the agonist group were administered GnRH agonist started 5 days before discontinuation of the oral contraceptive.
Study: NCT00748020

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: UVB phototherapy
Description: Group 1: every irradiation an increase of 40%, starting with 70% of the minimal erythema dose

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: UVB phototherapy
Description: Group 2: every irradiation an increase of 20%, starting with 30% of the minimal erythema dose
Study: NCT00568633

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Description: Allogeneic, 5+ of 6 HLA-matched PBSC transplant from sibling, mobilized to target of 5 x 10e6 CD34+ cells/kg and \< 7 x 10e8 CD3+ cells/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG)
Description: 1.5 mg/kg for 5 days by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CSP)
Description: 6.25 mg/kg twice daily oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: 15 mg/kg twice daily oral

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI)
Description: 80 cGy/fraction radiotherapy in 10 fractions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate
Description: 1.0 mg/kg for 5 days by IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best standard care
Description: Intervention consist of:~* Consolidation chemotherapy (3-4 cycles of cytarabine +/- an anthracycline agent, or other consolidation)~* Autologous transplantation~* Non-Myeloablative unrelated-donor transplant, +/- TLI and ATG conditioning~* Umbilical cord blood transplantation~* Haploidentical transplantation
Study: NCT00513825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: IV solution of NaCl 0.45% (Arm 1) or IV 75 cc of sodium bicarbonate 8.4% solved in 1 liter of NaCl 0.45% (Arm 2) . Each fluid is infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: IV solution of NaCl 0.45% (Arm 1) or IV 75 cc of sodium bicarbonate 8.4% solved in 1 liter of NaCl 0.45% (Arm 2) . Each fluid is infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
Study: NCT02983279

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Undergo caloric restriction diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo counselor-led dietary counseling
Study: NCT04364490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copernicus noVF
Description: Advanced gait training sessions by the computerized BWS system, named Copernicus®, without visual feedback.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copernicis VF-Plus
Description: Advanced gait training session with the addition of visual feedback ensuring a real-time interactive control of locomotor performance.
Study: NCT02983279

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic
Description: Undergo standard of care surgery
Study: NCT02524483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Challenge Program
Description: The Therapeutic Challenge Program will consist of a 5 minute warm-up, 20 minutes of challenging balance training, and 20 minutes of challenging treadmill and overground walking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise Program
Description: The Therapeutic Exercise Program will consist of 15 minutes of strength training and flexibility exercises, 15 minutes of balance exercises, and 15 minutes of treadmill walking.
Study: NCT04242641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WW
Description: WW is a structured lifestyle modification, weight-loss programme involving a programme for healthy eating, physical activity and positive mindset and support via attendance at local WW workshops and digital tools.
Study: NCT01251536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose escalation of cetuximab
Description: Dose, frequency \& treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly

Intervention type: DRUG
Group type: OTHER
Intervention: Standard first line treatment with cetuximab + Folfiri
Description: Dose, frequency \& treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab: 250 mg/m2 weekly.
Study: NCT01146457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Active dosage
Study: NCT04364490

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Usual care
Study: NCT04829162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother without obesity, daughter with obesity
Description: Participants in this group were shown an image of a mother without obesity and a daughter with obesity.
Study: NCT01146457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Active dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Active dosage